Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025

Rhea-AI Summary

Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care markets, has scheduled its first-quarter 2025 financial results announcement for May 8, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss financial results and business highlights.

Investors can access the live webcast through Vericel's Investor Relations website. Call participants can dial (800) 715-9871 domestically or (646) 307-1963 internationally. Presentation slides will be available on the webcast and investor relations section. A replay will remain accessible on the company website until May 8, 2026.

CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2025 financial results on Thursday, May 8, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time to register and download the required audio software, if necessary. Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website. 

To participate by telephone, please dial (800) 715-9871 or (646) 307-1963 if connecting from outside the U.S. When connected, please reference Vericel Corporation first-quarter 2025 earnings call to the operator.

A replay of the webcast will be available on the Vericel website until May 8, 2026.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid^® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com. Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2025 Vericel Corporation. All rights reserved.

Investor Contact:

Eric Burns
ir@vcel.com
+1 (734) 418-4411

FAQ

When will Vericel (VCEL) release Q1 2025 earnings?

Vericel will release its Q1 2025 earnings on Thursday, May 8, 2025, followed by a conference call at 8:30 a.m. ET.

How can investors join Vericel's Q1 2025 earnings call?

Investors can join via webcast at investors.vcel.com/events-presentations or by phone at (800) 715-9871 (US) or (646) 307-1963 (international).

How long will Vericel's Q1 2025 earnings call replay be available?

The earnings call replay will be available on Vericel's website until May 8, 2026.

What markets does Vericel (VCEL) operate in?

Vericel operates in the advanced therapies market, specifically focusing on sports medicine and severe burn care.